Dr. Reddy's Laboratories Ltd (RDY): Price and Financial Metrics
Dr. Reddy's Laboratories Ltd (RDY)
Today's Latest Price: $53.61 USD
Updated Jul 15 12:40pm
Add RDY to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 213 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
RDY Stock Summary
- Price to trailing twelve month operating cash flow for RDY is currently 0.23, higher than just 2.63% of US stocks with positive operating cash flow.
- With a year-over-year growth in debt of -41.16%, Dr Reddys Laboratories Ltd's debt growth rate surpasses just 6.64% of about US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for RDY comes in at 275.79% -- higher than that of 98.28% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Dr Reddys Laboratories Ltd, a group of peers worth examining would be AGCO, OPK, XYL, VAR, and HAS.
- RDY's SEC filings can be seen here. And to visit Dr Reddys Laboratories Ltd's official web site, go to www.drreddys.com.
RDY Stock Price Chart Technical Analysis Charts
RDY Price/Volume Stats
| Current price | $53.61 | 52-week high | $55.19 |
| Prev. close | $53.01 | 52-week low | $33.33 |
| Day low | $53.51 | Volume | 42,985 |
| Day high | $53.97 | Avg. volume | 216,758 |
| 50-day MA | $52.14 | Dividend yield | 0.51% |
| 200-day MA | $44.38 | Market Cap | 8.88B |
Dr. Reddy's Laboratories Ltd (RDY) Company Bio
Dr. Reddy's Laboratories operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company was founded in 1984 and is based in Hyderabad, India.
RDY Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $53.61 | $2493.66 | 4752% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Dr Reddys Laboratories Ltd. To summarize, we found that Dr Reddys Laboratories Ltd ranked in the 95th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 4776.17%. As for the metrics that stood out in our discounted cash flow analysis of Dr Reddys Laboratories Ltd, consider:
- The business' balance sheet reveals debt to be 3% of the company's capital (with equity being the remaining amount). Approximately only 10.74% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- RDY's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 50.45% of tickers in our DCF set.
- As a business, Dr Reddys Laboratories Ltd experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than just 0% of stocks generating free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 4657% |
| 1% | 4705% |
| 2% | 4752% |
| 3% | 4800% |
| 4% | 4848% |
| 5% | 4895% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as RDY, try THC, VASO, DVCR, CORT, and FVE.
Loading social stream, please wait...